New research presented at the American Thoracic Society virtual symposium showed the first-in-class drug reduced severe asthma exacerbation rate by 35% vs placebo.
In COPD patients, a new study found no association between lung function decline and individual CVD outcomes, but disease exacerbations and dyspnea were implicated.
Mepolizumab (Nucala) received a new indication for the treatment of hypereosinophilic syndrome in patients aged ≥12 years.
Along with COPD, fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) is now approved for the treatment of asthma in patients aged ≥18 years.
A new survey found adolescents who have ever used e-cigarettes are 5-times more likely to receive a COVID-19 diagnosis. More results at-a-glance in our new slideshow.
A new survey suggests use of e-cigarettes and dual use of e-cigarettes and traditional cigarettes are significant underlying risk factors for COVID-19 among US adolescents.
New research presented at the American Thoracic Society 2020 Virtual meeting showed the novel Theraflu Home FluTest demonstrated good sensitivity and specificity for influenza A and B viruses.
New research presented at the ATS 2020 Virtual meeting shows adolescents who use e-cigarettes along with marijuana and/or cigarette smoking have significantly higher odds of lifetime asthma.
The proposed recommendations will allow more women and black patients to be eligible for lung cancer screening.